
Huisheng Biopharmaceutical
Huisheng Biopharmaceutical is a Chinese pharmaceutical company focused on diabetes and its complications across biologics and chemical drugs.
- Company
- Changchun, Jilin, CNChina

Huisheng Biopharmaceutical is a Chinese pharmaceutical company focused on diabetes and its complications across biologics and chemical drugs.
huishengpharm.comCrawled Oct 25, 2026
Huisheng Bio-Pharmaceutical Co., Ltd. is a comprehensive pharmaceutical company under the Four Rings Medical Group, specializing in diabetes and complication treatments. It covers biopharmaceutical and chemical pharmaceutical products with a complete product pipeline, established in 2014 under the Four Rings Group.
Tonghua Dongbao Pharmaceuticals secures exclusive rights in China for Huisheng Biopharma’s first domestically produced **Insulin Degludec** biosimilars, **Huiyoujia** (Insulin Degludec/Insulin Aspart) and **Huiyouda**. The agreement enables joint commercialization of these next-generation basal insulin treatments, expanding access to advanced diabetes care in the country.
Feb 2026Insight, China's Pharmaceutical IndustryNews article
Sihuan Pharmaceutical leads China’s insulin market through its subsidiary, Huisheng Biopharma. The company secures marketing approval for two home-grown insulin products, expanding its domestic presence in diabetes treatment. These developments position Sihuan as a key player in insulin innovation within the country.
Aug 2024vocusNews article
Sihuan Pharmaceutical Holdings Group announces regulatory approval for a new diabetes drug. The company, listed on the Hong Kong Stock Exchange, has not disclosed further details about the medication or its development timeline in the update.
Aug 2024TipRanksNews article
Sihuan Pharmaceutical Holdings Group Ltd. secures **NMPA registration approval** for **Proline Janagliflozin tablets (Huiyoujing)**, a **Class 1 innovative SGLT-2 inhibitor** developed by its subsidiary **Huisheng Biopharmaceutical**. The drug targets diabetes treatment under China’s national medical regulatory framework. The approval marks a milestone for the company’s pipeline of novel therapies.
Jan 2024MarketScreener IndiaNews article